ArticlePharmaceuticals (Basel, Switzerland)2022

Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer.

Matteo Franchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.